Exciton Technologies receives FDA approval to market exSALT(TM)

    EDMONTON, Aug. 5 /CNW/ - Exciton Technologies Inc. today announced that
the Company has received approval from the United States Food and Drug
Administration (FDA) to market exSALT(TM) SD7 Wound Dressing, a product
incorporating Exciton's patented platform coating technology utilizing silver
oxysalts as the active ingredient.
    "This achievement represents a significant team effort and a strong
belief in our product," stated Rod Precht, Exciton's President and Chief
Executive Officer. "To date, our technologies have demonstrated superior
attributes over other leading silver technologies, allowing us to offer
effective products at a significantly lower cost. With the approval from the
FDA, we can now finalize our commercialization efforts to launch the
exSALT(TM) dressing in North America later this year. In addition to preparing
for the launch of the exSALT(TM) dressing, the Company is currently in the
process of negotiating licensing and distribution agreements with leading
wound care companies to broaden our marketing network globally."
    The global wound-care market was $14 billion in 2008 and is expected to
exceed $17 billion by 2012. Although silver-based products currently comprise
a relatively small portion of this market, it is rapidly growing by 25%
annually and is expected to grow to $750 million by 2015 due to the natural
therapeutic benefits of silver. According to the Centers for Disease Control
and Prevention, hospital-acquired infections in the United States alone cost
up to $30 billion a year. Exciton's silver-based products have the potential
to capitalize an even larger market by:

    -   Utilizing a more active form of silver;
    -   Reducing costs; and
    -   Being amendable to more applications such as consumer products,
        catheters and orthopedic devices.

    About exSALT(TM)
    Silver has powerful antimicrobial properties. In the proper chemical
form, it is proven as a highly effective wound-care agent with important
benefits for promoting healing and preventing infection. Exciton's exSALT(TM)
antimicrobial technology uses a patented chemical deposition technique to form
a coating of active species of silver on a wide range of materials. The
exSALT(TM) SD7 Wound Dressing targets the advanced wound care market in
preventing infection during the treatment of burn and chronic wounds such as
diabetic foot ulcers and bed sores. By adjusting the dose of silver and
expanding the number of product configurations, Exciton can target a greater
portion of the overall market.

    About Exciton Technologies Inc.
    Exciton Technologies Inc. is an Alberta advanced materials research and
development company focused on the creation of technologies for preventing and
controlling infection. Currently our valuable portfolio of patentable platform
technologies is based on the antimicrobial properties of silver. The Company's
technologies offer next-generation, less expensive and environmentally
friendly products, enabling the company to participate in many industries,
including the wound care and disinfectant markets.

    Forward-looking Statements
    This press release may contain forward-looking statements. Forward
looking statements, including the Company's belief as to the potential of its
products, the Company's expectations regarding the issuance of additional
patents and the Company's ability to protect its intellectual property,
involve known and unknown risks and uncertainties, which could cause the
Company's actual results to differ materially from those in the forward
looking statements. Such risks and uncertainties include, among others, the
availability of funds and resources to pursue research and development
projects, the ability to economically manufacture its products, the potential
of its products, the success and timely completion of clinical studies and
trials, the Company's ability to successfully commercialize its products, the
ability of the Company to defend its patents from infringement by third
parties, and the risk that the Company's patents may be subsequently shown to
be invalid or infringe the patents of others. Investors should consult the
Company's quarterly and annual filings with the Canadian commissions for
additional information on risks and uncertainties relating to the forward-
looking statements. Investors are cautioned against placing undue reliance on
forward-looking statements.

For further information:

For further information: Rod Precht, President & CEO, Exciton
Technologies Inc., Phone: (780) 722-1666, E-mail: rprecht@exitontech.com;
Stephanie Gillis-Paulgaard, Director, Investor Relations, Exciton Technologies
Inc., Phone: (780) 964-6410, E-mail: spaulgaard@excitontech.com

Organization Profile

Exciton Technologies Inc.

More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890